July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
MIRNA-18A IS A KEY REGULATOR OF HUMAN TRABECULAR MESHWORK CELL RESPONSE TO TGFΒ; IMPLICATIONS FOR GLAUCOMA
Author Affiliations & Notes
  • John Knox
    Department of Eye and Vision Science, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom
  • Karen Lester
    Department of Eye and Vision Science, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom
    Genomic Medicine Group, Biomedical Sciences Research Institute, Ulster University, Northern Ireland, United Kingdom
  • Kevin Hamill
    Department of Eye and Vision Science, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom
  • Colin Willoughby
    Department of Eye and Vision Science, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom
    Genomic Medicine Group, Biomedical Sciences Research Institute, Ulster University, Northern Ireland, United Kingdom
  • Footnotes
    Commercial Relationships   John Knox, None; Karen Lester, None; Kevin Hamill, None; Colin Willoughby, None
  • Footnotes
    Support  Fight for Sight (UK)
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 5651. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      John Knox, Karen Lester, Kevin Hamill, Colin Willoughby; MIRNA-18A IS A KEY REGULATOR OF HUMAN TRABECULAR MESHWORK CELL RESPONSE TO TGFΒ; IMPLICATIONS FOR GLAUCOMA. Invest. Ophthalmol. Vis. Sci. 2019;60(9):5651.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Primary open angle glaucoma (POAG) results from defective extracellular matrix (ECM) deposition and turnover by trabecular meshwork (TM) cells, driven by an increase in TGFβ signalling. Connective tissue growth factor (CTGF) is a key downstream mediator of the ECM effects of TGFβ, and has been shown to also have increased expression in the aqueous humor of POAG patients. Identifying regulators of this response could lead to new therapeutic targets. MiRNA-18a, -19a, -19b, -199a, -199b, -26a, -26b, -133b and -205 have been shown to regulate the TGFβ/CTGF response in other tissues. Here we investigated the change in expression of these miRNAs in human TM (HTM) after TGFβ treatment, and what effect they have on CTGF expression in response to TGFβ.

Methods : TM cells from 5 human donors were treated with 5 ng/ml TGFβ for 24 hours and the expression of miRNAs, CTGF mRNA and protein were measured. HTM cells from three donors were treated with 5 ng/ml TGFβ and cotransfected with 100 nM of miRNA mimic, miRNA inhibitor or a scrambled control for 24 hours. The mRNA and protein expression of CTGF was measured, and compared to HTM treated with TGFβ without cotransfection.

Results : Although the expression of CTGF increased after TGFβ treatment in HTM cells from all donors, miRNA responses were variable between donors with only miR-18a showing a consistent upregulation, with an average 1.44±0.22-fold increase (mean±SD, n=5, p<0.001). With this in mind, we further investigated the effect of miR-18a on the TGFβ-induced expression of CTGF. Cells transfected with a miR-18a mimic showed a 0.57±0.30-fold reduction in the transcript abundance of CTGF (mean±SD, n=3, p<0.01), and a 0.411±0.020-fold reduction in the protein abundance (mean±SD, n=3, p<0.0001). Inhibiting miR-18a had no significant effect on CTGF expression.

Conclusions : These data suggest that increasing miR-18a expression can decrease the TFGβ-induced expression of CTGF in HTM cells. MiR-18a mimics or upregulation represent a viable therapeutic strategy for treating the TGFβ-induced changes to the TM in glaucoma.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×